A phase ii study of the combination of etoposide and cisplatin in the therapy of advanced gastric cancer

✍ Scribed by Thomas E. Elliott; Charles G. Moertel; Harry S. Wieand; Richard G. Hahn; James B. Gerstner; Loren K. Tschetter; James A. Mailliard

• Publisher: John Wiley and Sons
• Year: 1990
• Tongue: English
• Weight: 413 KB
• Volume: 65
• Category: Article
• ISSN: 0008-543X
• DOI: 10.1002/1097-0142(19900401)65:7<1491::aid-cncr2820650707>3.0.co;2-g

✦ Synopsis

Forty-eight patients with advanced gastric cancer and measurable areas of malignant disease were treated with etoposide (130 mg/mz/day X 3 days) plus cisplatin (45 mg/mzday on days 2 and 3). Both drugs were given by constant intravenous infusion and repeated every 4 weeks. Common toxic reactions included nausea, vomiting, diarrhea, alopecia, peripheral neuropathy, leukopenia, and thrombocytopenia. Most patients experienced severe but reversible toxic reactions. In 46 evaluable patients an overall objective regression rate of 28% was obtained with a median duration of regression of 4 months. Regression rates were only modestly reduced among patients with prior chemotherapy exposure (21%). Whereas this combination of etoposide and cisplatin does not appear to offer any major advantage over other single and combination regimens in the treatment of advanced gastric cancer, it shows definite activity and its lack of cross-resistance with other commonly used agents for this disease could indicate a possible role in new combination or sequential chemotherapy approaches. As an interesting sidelight, we found that 21% of our patients had elevated human chorionic gonadotropin (HCG) levels, and among this group regression rates were higher than in HCG-negative patients. It would be of interest to extend these observations in other gastric carcinoma studies involving cisplatin regimens.